首页> 外文期刊>Bosnian Journal of Basic Medical Sciences >Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma
【24h】

Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma

机译:甲状腺乳头状癌的淋巴管浸润与临床病理特征的关系

获取原文
           

摘要

Lymphovascular invasion (LVI) is an important prognostic factor in various solid tumors, however, data on the association between LVI and thyroid carcinomas are limited. In this study, we evaluated the relationship between LVI and clinicopathological features of papillary thyroid carcinoma (PTC). Six hundred seventy-eight patients diagnosed with PTC between 2012 and 2015 were included into the study. Patients were classified based on the presence or absence of LVI. Gender, age, ultrasonography (US), tumor size and multifocality, BRAFV600E mutation, perineural and capsular invasion, extrathyroid extension (ETE), nodal metastasis, and recurrences were evaluated, and risk analysis was performed for each parameter. The number of patients with LVI [LVI (+)] was 63, while the number of patients without LVI [LVI (-)] was 615. The female/male ratio was 564/114. LVI was present in 18.4% of male patients and in 7.4 % of female patients. In the age group between 17-25 years LVI was detected in 6/13 patients, and this result was statistically significant compared to other age groups ( p = 0.004). Suspicious lymph nodes upon US, perineural or capsular invasion, ETE, tumor size, and nodal metastasis were significantly more frequent in LVI (+) group ( p < 0.001). The frequency of BRAFV600E mutation was also significantly higher in LVI (+) group ( p < 0.001). Overall, the presence of LVI was associated with gender, tumor size, age, lymph node metastasis, pathological lymph nodes, perineural and capsular invasion, ETE, and BRAFV600E mutation. These results suggest that in PTC patients undergoing thyroidectomy, the presence of LVI should be considered as an indicator of aggressive clinicopathological features and those patients should be followed up carefully for recurrences and metastasis.
机译:淋巴管浸润(LVI)是各种实体瘤的重要预后因素,但是,有关LVI与甲状腺癌之间关联的数据有限。在这项研究中,我们评估了LVI与乳头状甲状腺癌(PTC)的临床病理特征之间的关系。 2012年至2015年期间诊断为PTC的687例患者被纳入研究。根据是否存在LVI对患者进行分类。评估性别,年龄,超声(US),肿瘤大小和多灶性,BRAFV600E突变,神经周和包膜浸润,甲状腺外扩展(ETE),淋巴结转移和复发,并对每个参数进行风险分析。 LVI [LVI(+)]的患者人数为63,而没有LVI [LVI(-)]的患者人数为615。男女比例为564/114。 LVI在男性患者中占18.4%,在女性患者中占7.4%。在17-25岁之间的年龄组中,有6/13位患者检测到LVI,与其他年龄组相比,该结果具有统计学意义(p = 0.004)。 LVI(+)组中因US,神经周或囊膜浸润,ETE,肿瘤大小和淋巴结转移而引起的可疑淋巴结明显增多(p <0.001)。 LVI(+)组的BRAFV600E突变频率也明显更高(p <0.001)。总体而言,LVI的存在与性别,肿瘤大小,年龄,淋巴结转移,病理性淋巴结,神经周和包膜浸润,ETE和BRAFV600E突变有关。这些结果表明,在接受甲状腺切除术的PTC患者中,应将LVI的存在视为侵略性临床病理特征的指标,并应仔细随访这些患者的复发和转移情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号